Wolverine Trading’s Puma Biotechnology PBYI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Sell
-12,944
Closed -$40.4K 4762
2023
Q1
$37K Buy
+12,944
New +$48.8K ﹤0.01% 3895
2022
Q1
Sell
-11,847
Closed -$30.6K 6178
2021
Q4
$38K Buy
+11,847
New +$51.4K ﹤0.01% 5403
2021
Q1
Sell
-14,810
Closed -$154K 6265
2020
Q4
$154K Buy
14,810
+4,151
+39% +$42K ﹤0.01% 4350
2020
Q3
$107K Buy
+10,659
New +$109K ﹤0.01% 4111
2020
Q2
Sell
-19,008
Closed -$197K 5063
2020
Q1
$160K Sell
19,008
-3,968
-17% -$38.5K ﹤0.01% 3798
2019
Q4
$193K Buy
22,976
+5,618
+32% +$46.5K ﹤0.01% 4040
2019
Q3
$194K Buy
17,358
+5,642
+48% +$60.9K ﹤0.01% 3609
2019
Q2
$149K Buy
11,716
+344
+3% +$7.92K ﹤0.01% 3862
2019
Q1
$441K Buy
11,372
+425
+4% +$13K ﹤0.01% 2914
2018
Q4
$231K Sell
10,947
-349
-3% -$10.5K ﹤0.01% 3535
2018
Q3
$518K Sell
11,296
-128
-1% -$6.17K ﹤0.01% 3072
2018
Q2
$777K Hold
11,424
﹤0.01% 2535
2018
Q1
$777K Buy
11,424
+8,805
+336% +$659K ﹤0.01% 2535
2017
Q4
$259K Buy
2,619
+43
+2% +$4.81K ﹤0.01% 3815
2017
Q3
$308K Sell
2,576
-3,623
-58% -$337K ﹤0.01% 3220
2017
Q2
$538K Buy
+6,199
New +$347K ﹤0.01% 2360

Other funds holding PBYI

Wolverine Trading's PBYI Position: Q2 2023 in Review

Wolverine Trading sold out of Puma Biotechnology (PBYI) in Q2 2023, closing a stake of 12,944 shares — an estimated $40.4K sold.

Wolverine Trading first reported a position in PBYI in Q2 2017 and held it in 16 quarters. The position peaked at $777K in Q2 2018. 68 funds tracked by Wall St. Rank hold PBYI as of Q2 2023.

  • Wolverine Trading reported no remaining Puma Biotechnology position as of Q2 2023 after selling out during the quarter.
  • Wolverine Trading sold 12,944 Puma Biotechnology shares in Q2 2023, an estimated $40.4K.
  • Wolverine Trading first reported a position in Puma Biotechnology in Q2 2017 and held it in 16 quarters.
  • Wolverine Trading's Puma Biotechnology position peaked at $777K in Q2 2018.
  • 68 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2023.

Based on Wolverine Trading's 13F filing for Q2 2023, filed 23 Aug 2023.